Thimet oligopeptidase (TOP) is a thiol-and metallo-dependent peptidase and has been shown to be one of the β-secretase candidates. TOP expressed in COS cells cleaved amyloid precursor protein (APP) at the β-secretase site, and we found a proteolytic product of APP called secreted form of APP by β-secretase (sAPPβ) in the conditioned media. Here we demonstrate that sAPPβ was increased in conditioned media when TOP was coexpressed in COS cells with APP and treated with an ADAM inhibitor SI-27. In addition, although TOP expressed in COS cell was localized at nuclei or Golgi apparatus, it exclusively colocalized at Golgi apparatus when APP was coexpressed with TOP.
Introduction
Alzheimer's disease is characterized by the formation of amyloid plaques containing amyloid β-protein (Aβ) in brain regions important for intellectual function and deposition of Aβ brings about neuronal death and a progressive loss of cognitive function and memory. Aβ, a 39-43 amino acid peptide, is generated by the proteolytic processing of amyloid precursor protein (APP) by β-and γ -secretases (Goldgaber et al., 1987; Kang et al., 1987; Robakis et al., 1987; Tanzi et al., 1987) . APP metabolism is normally processing at the Aβ domain (16 amino acid residues from N-terminus of Aβ) by α-secretase and nonamyloidogenic N-terminal fragment of APP (sAPPα) is secreted from the cells (Schubert et al., 1989; Weidemann et al., 1989; Esch et al., 1990; Sisodia et al., 1990; Wang et al., 1991) . Therefore, APP processing at the α-secretase site dominantly occurs in the normal brain, but in the Alzheimer's brain, β-and γ - Figure 1 . The cleavage activity for KM-QFS and NL-QFS of purified hTOP is specifically inhibited by metalloprotease inhibitors. The β-secretase activities for KM-and NL-QFS were determined as described in the Materials and Methods section. Columns 1 and 2 are negative control containing EDTA and positive control containing MnCl 2 in assay buffer, respectively. Columns 3-7 are pepstatin, E-64, TLCK, phosphoramidon, and BE16627B (final concentrations; 10 µg/ml), respectively. The white and black columns are the activities for KM-QFS and NL-QFS, respectively. secretases are activated and Aβ is produced. However, a small amount of Aβ is secreted in the normal cultural medium, and Aβ deposition is also detected in the normal brain (Haass et al., 1992; Seubert et al., 1992; Shoji et al., 1992) . Consequently, APP metabolism is fluctuating to some extent and balance of α-and β-secretase activity could regulate the onset of Alzheimer's disease.
Previously, we reported that the purification of a β-secretase candidate, thimet oligopeptidase (TOP, EC 3.4.24.15), from bovine brain. In addition, we coexpressed human TOP and APP695 in COS cells and found that the amount of secreted sAPPβ is increased in conditioned media (Koike et al., 1999a) . Independently, we reported that the membrane anchored metalloprotease MDC9 has an α-secretase activity and activation of α-secretase suppresses the secretion of sAPPβ (Koike et al., 1999b) . In this article, we describe that the expression of TOP decreases sAPPα secretion into conditioned media and addition of a metalloprotease inhibitor enhanced the secretion of sAPPβ. We also show that TOP and APP are colocalized in the same compartment in COS cells.
Materials and methods

Assay for β-secretase
The quenched fluorescent substrates (QFS) for β-secretase, normal KM-QFS (7-methoxycoumarin-4-acetyl-SEVKMDAEFR-K(RR-NH 2 )-(2,4-dinitrophenyl)), and Alzheimer NL-QFS (7-methoxycoumarin-4-acetyl-SEVNLDAEFR-K(RR-NH 2 )-(2,4-dinitrophenyl)) were synthesized by Peptide Institute Inc. (Minoh, Japan). A KRR sequence was added for easy solubilization. The human TOP (hTOP) expressed COS cells was purified by Ni-NTA column as described (Koike et al., 1999a) . hTOP (2 µg) was assayed in 200 µl of buffer A (25 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1 mM DTT, 10 µg/ml leupeptin and 100 µM PMSF) containing 5 mM EDTA or MnCl 2 . Substrate (1 mM in DMSO) was added to a final concentration of 5 µM, and the assay mixtures were incubated at 37 • C for 30 min. The addition of 100 µl of 10% sodium dodecyl sulfate (SDS) and 700 µl of 100 mM sodium acetate (pH 4.0) stopped the reactions. Fluorescence value was measured on a JASCO FP-777 fluorescence spectrometer (excitation, 328 nm; emission, 393 nm). Various inhibitors (E-64, TLCK: N α -tosyl-L-lysyl chloromethyl ketone, pepstatin, phosphoramidon and BE16627B: hydroxamate-based metalloprotease inhibitor (A. Okuyama, unpublished data) )were used to determine protease activity for KM-and NL-QFS.
Co-expression of human TOP and APP695 in COS cells and immunoblot analysis
Human APP695 cDNA fragment (APP-WT, wild type APP) was constructed with the p91023 vector. hTOP cDNA fragment was constructed with pSecTag vector (Invitrogen, San Diego, CA, U.S.A.). An APP plasmid and hTOP plasmid were used to transfect COS-7 cells by the electroporation method (Chu et al., 1987) . After 12 h incubation, transfected cells were transferred into serum-free medium with or without a hydroxamatebased cell-permeable metalloprotease inhibitor: SI-27 (final concentration 20 µg/ml). After 72 h incubation, transfected cells were harvested and sonicated in 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, and 1% Triton X-100. After centrifugation at 8000/,×/,g for 5 min, the protein concentration of the supernatant was determined. The supernatant was diluted in 2/,×/,SDS-buffer (125 mM Tris-HCl, pH 6.8, 30% glycerol, 2% SDS, 5% β-mercaptoethanol, and 0.2% bromophenol blue). The conditioned medium (8 ml) was concentrated by the addition of trichloroacetic acid (TCA; final concentration 10%) and centrifuged at 10 000/,×/,g for 15 min. The precipitate was washed with ether-ethanol (1:1) and then dissolved in 300 µl of 2/,×/,SDS-buffer. The samples were subjected to electrophoresis in 10% polyacrylamide gels (Laemmli, 1970) and then transferred onto a polyvinylidene difluoride (PVDF) membrane (Nihon Eido, Tokyo, Japan). The transferred membrane was incubated with anti-APP antibodies overnight at 4 • C, visualized with a VECTASTAIN Elite ABC kit (Vector Lab., Burlingame, CA, U.S.A.) and finally with a POD immunostain set (Wako, Osaka, Japan). The anti-APP antibodies used were anti-22C11 antibody (Boeringer Mannheim, Germany), anti-Aβ1-16 antibody (Kinouchi et al., 1995) and anti-sAPPβ antibody (Koike et al., 1999) . The anti-TOP antibodies were raised according to Koike et al. (1999a) . The detected bands were quantified with an Imagemaster Ver. 2.0 (Pharmacia, Uppsala, Sweden).
Immunofluorescence microscopy
For indirect immunofluorescence microscopy, COS cells transfected with hTOP or APP695-WT, were grown under the conditions described above and fixed in 5% formaldehyde for 20 min at 37 • C. After washing with PBS, the fixed cells were permeabilized with 0.2% Triton X-100, 1 mM mgCl 2 , and 0.1 mM CaCl 2 in PBS for 5 min at room temperature. The preparations were treated with blocking solution (1% normal donkey serum in PBS) for 30 min, and soaked in the first anti-C100 antibody (Kouchi et al., 1998 ) and anti-myc antibody (Invitrogen) for 1 h at 37 • C. The cells were then washed three times with PBS and incubated with the second Oregon Green TM -conjugated anti-rabbit IgG and rhodamine-conjugated anti-mouse IgG antibodies (Molecular Probes Inc., Eugene, OR, U.S.A.) for 1 h at 37 • C. The cells were viewed and examined with a confocal scanner (Leica).
Results and discussion
Inhibition of β-secretase activity by metalloprotease inhibitors
Previously, we reported that hTOP has a β-secretase activity toward APP as a substrate as well as synthetic KM-or NL-QFS. To know the specificity of TOP, we determined the inhibitory profile of TOP (Figure 1) . hTOP was strongly inhibited by metalloprotease inhibitors (phosphoramidon, BE16627B) and chelating agents (EDTA, 1,10-phenanthroline), but other protease inhibitors (E-64, cysteine protease inhibitor; TLCK, serine protease inhibitor; pepstatin, aspartate protease inhibitor) had no effect. Both KM-QFS and NL-QFS were directly cleaved by hTOP in the presence of metal ions and reducing agent. Interestingly, fluorescence intensities were higher at NL-QFS than KM-QFS under all conditions. NL-QFS was synthesized according to β-secretase flanking site of Swedish Alzheimer APP mutant, in which Aβ was drastically increased. These results indicate that hTOP directly cleaved the β-secretase substrates, and hTOP has a higher activity toward Swedish APP mutant.
Increase in sAPPβ secretion by α-secretase inhibitor
In the previous study, we reported that sAPPα secretion in APP-WT overexpressing cells increased with TPA, and it decreased by the addition of α-secretase inhibitor SI-27. However, sAPPβ was reciprocally increased by SI-27 treatment (Koike et al., 1999b) . It could be possible that the APP metabolism including β-secretase and α-secretase pathways are equally balanced.
To confirm this, we tried to inhibit endogenous α-secretase activity. We coexpressed APP-WT and/or hTOP in COS cells with/without SI-27. 
Change in the cellular localization of hTOP
Finally, we immunostained APP-WT and/or hTOPtransfected COS cells with anti-C100 and/or anti-myc antibody. Figure 3A showed no fluorescence was observed in vector-transfected cells. APP-WT-or hTOPtransfected cell was stained mainly at Golgi apparatus or nucleus plus Golgi apparatus, respectively (Figures 3B and 3C ). On the other hand, APP-WT/hTOPcotransfected cell was stained mainly Golgi-like apparatus ( Figures 3D-F) . These results suggest that single-expressed hTOP is mainly localized at nuclei, but a small amount of TOP is attached to Golgi apparatus, while hTOP coexpressed with APP-WT colocalized with APP in Golgi apparatus. It was generally said that TOP was a cytoplasmic protease (Orlowski et al., 1983; Silva et al., 1999) . However, TOP was also purified from microsomal fraction of the porcine brain (Akopyan et al., 1994) . From these results, we predict that the localization of hTOP may change upon unidentified signal(s).
In the present study, TOP expressed in COS cells increased the secretion of sAPPβ (Figure 2, lane 3) , and enhanced sAPPβ secretion is promoted by the SI-27 treatment (Figure 2, lanes 2 and 4) . In contrast, sAPPα secretion was decreased in the SI-27 treated condition or TOP coexpressed condition (Figure 2,  lanes 2 and 3) . Recently a novel β-secretase candidate was cloned. Using an expression cloning strategy to identify β-secretase gene that changes in Aβ level, Vassar et al. (1999) isolated a protease clone that shared sequence similarity with a lysosomal aspartic protease cathepsin E. Overexpression of this brainspecific membrane-bound protease, termed BACE (beta-site APP cleaving enzyme)/Asp2/p501 (Vassar et al., 1999; Yan et al., 1999; Sinha et al., 1999) , increased the peptide cleavage as well as sAPPβ production with concomitant decrease in sAPPα. In addition, a substantial proportion of BACE immunostaining appeared in the Golgi apparatus like TOP and endosome. Robust expression of BACE in pancreatic acinar cells (Vassar et al., 1999; Yan et al., 1999) needs further explanation. These and our results suggest that many proteases have a secretase activity for APP.
In conclusion, we have demonstrated that the APP metabolism is regulated by the balance of α-secretase (MDC9, TACE, etc.) and β-secretase (TOP, BACE etc.) activities and that hTOP is one of the β-secretase candidates in living cells.
